Two compounds carry the gut-health application: KPV for inflammation modulation and BPC-157 oral for mucosal repair. Both have the unusual property of working locally in the GI tract from oral dosing, sidestepping most of the systemic-exposure question that dominates the rest of this catalogue. LL-37 is the high-risk antimicrobial branch for selected chronic-infection cases and lives outside the wellness frame.
The audience this site is written for is probably already familiar with the dietary, FODMAP, fibre, and fermented-food levers. None of the peptides below replaces a structurally bad diet, untreated H. pylori, undiagnosed coeliac, or active IBD that needs proper gastroenterology workup. They’re the marginal lever for users who’ve done that groundwork.
The shortlist
KPV - gut-targeted inflammation control
- What it is. A 3-amino-acid peptide (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH. The smallest peptide in this catalogue.
- Mechanism. Oral KPV is taken up via the PepT1 transporter on enterocytes, delivering the compound directly to the inflamed mucosa. Inhibits NF-κB activation in keratinocytes and gut epithelial cells; modulates mast cell activation; reduces pro-inflammatory cytokine cascades.
- Evidence framing. Tier: Preclinical (Dalmasso 2008 DSS-colitis mouse model, multiple in-vitro NF-κB studies). Tier: Limited data for human protocols - no large RCTs, but the mechanism is well-characterised and the community use case for inflammatory bowel patterns is consistent.
- Protocol. 250–500 mcg orally twice daily. Capsules or stable liquid formulation. Effects are local / mucosal, so subcutaneous gives a different (more systemic) profile that’s not the goal here.
- Where it fits. IBD-adjacent presentations (Crohn’s and UC users in remission looking for adjunct inflammation control), SIBO with high inflammatory load, post- gastroenteritis recovery, mast-cell-pattern gut symptoms.
BPC-157 oral - mucosal repair
- What it is. The same BPC-157 used systemically for tendon / joint healing, but delivered orally where the unique gastric-juice stability profile becomes load-bearing - BPC is one of the few peptides that survives the stomach intact.
- Mechanism for gut. Direct mucosal contact with inflamed / ulcerated GI lining; angiogenic and growth-factor signal promotes repair. Animal models show acceleration of gastric ulcer healing, IBD-model mucosal recovery, and esophageal protection against NSAID-induced damage.
- Evidence framing. Tier: Preclinical (extensive Sikiric / Seiwerth body of work, mostly rat models; consistent results across decades). Tier: Limited data for human protocols. Strong community track record for gut indications specifically - this is the application where BPC has the cleanest reputational signal.
- Protocol. 250–500 mcg orally twice daily. Arginine-salt formulation is the community-preferred form for oral stability. Cycle 4–8 weeks, then washout; the standard angiogenic-cycling rule applies even for oral local use.
- Where it fits. Post-NSAID gastritis, ulcer healing adjunct, post-gut-infection recovery, anastomotic / surgical recovery (clinical guidance), leaky-gut presentations where mucosal integrity is the limiter.
LL-37 - the high-risk antimicrobial branch
- When it’s on the table. Suspected biofilm SIBO that’s recurred after standard antibiotic protocols, or chronic-infection presentations where culture / breath-test data suggests an antimicrobial-resistant population.
- Why it’s risky here. Same Herxheimer issue as systemic LL-37 (rapid bacterial lysis, LPS release, inflammatory overshoot) but in the gut the LPS load can dump straight into portal circulation. Plus: autoimmune-flare risk in users with psoriasis / lupus / rosacea remains the same regardless of indication.
- Protocol if used. Same low-and-slow titration (50 mcg/d → 100–150 mcg/d over 2 weeks), paired with a binder (activated charcoal, bentonite clay) 30–60 min after each dose. 4–6 week cycle limit. See Immune Resilience for the broader LL-37 framing.
- Hard contraindications. Active autoimmune disease, especially psoriasis / lupus / rosacea / IBD-active flare (LL-37 in active IBD can worsen the inflammatory cascade despite the antimicrobial intent).
What’s NOT in the gut stack
- Systemic SC BPC-157 as a primary gut tool. If the goal is local mucosal action, oral is the route. SC BPC has its own indications (tendon, joint, systemic healing) covered in Injury Recovery.
- Subcutaneous KPV for gut symptoms. SC KPV is systemic anti-inflammatory; for gut-specific outcomes oral is where the PepT1 mucosal-uptake mechanism delivers.
- BPC + LL-37 stacked. Both are biofilm-active in different ways; the angiogenic + antimicrobial combination during active IBD flares is exactly the wrong direction.
- Prokinetic / motility peptides. Out of scope for this catalogue; the constipation / motility question is a different application class.
Decision guide
- Have you ruled out structural causes?
→ H. pylori, coeliac (transglutaminase IgA), active IBD needing flare control. Treating "leaky gut" with peptides while untreated H. pylori is causing the symptoms is the wrong layer. - Goal: inflammation modulation, IBD-adjacent
symptoms?
→ Oral KPV first-line. - Goal: mucosal repair, post-NSAID damage, ulcer
history?
→ Oral BPC-157 first-line. - Goal: both inflammation and repair?
→ KPV + oral BPC stacked. The community-stable "BPC/KPV blend" is the standard formulation here. - Suspected biofilm SIBO, no autoimmune history,
standard antibiotics already tried?
→ LL-37 enters the conversation with extreme caution. Not an early-stage option. - Active IBD flare?
→ Stay with the gastroenterologist’s protocol. Peptides aren’t flare control; they’re remission adjuncts.
Representative stacks
Stack 1 - Inflammation + repair (default IBD-adjacent)
- KPV 250–500 mcg orally twice daily
- BPC-157 250–500 mcg orally twice daily, arginine-salt form
- 4–8 week cycle, 4-week washout
- Symptom journal week-by-week (stool consistency, pain, energy, appetite)
Stack 2 - Repair-only (post-NSAID gastritis, ulcer history)
- Oral BPC-157 250–500 mcg twice daily, 4–6 weeks
- Stop NSAID where possible during the cycle
- PPI co-treatment per gastroenterology if active erosion or bleeding history
Stack 3 - LL-37 biofilm (advanced operators only)
- LL-37 start 50 mcg SC daily, titrate to 100–150 mcg over 2 weeks
- Activated charcoal or bentonite clay 30–60 min post-injection during titration
- Hydration emphasis - LPS clearance is renal
- 4–6 weeks max; clinical reassessment before any re-run
What stops people
- Treating peptides as flare control. Active Crohn’s or UC flares need proper gastroenterology management. Peptides are remission-phase adjuncts, not flare-control tools.
- Ignoring H. pylori / coeliac workup. Two of the most common structural causes of "leaky gut" symptoms. Treating either with KPV is the wrong layer.
- Stacking SC BPC + oral BPC. Doubles up on angiogenic exposure with overlapping mechanisms. Pick the route matching the goal.
- LL-37 with autoimmune predisposition. Same rule as in the immune-resilience application: psoriasis / lupus / rosacea / IBD-active are hard contraindications.
- Counterfeit oral peptide blends. Stable oral formulations are non-trivial; the grey market has plenty of "BPC/KPV oral" products that contain little or no actual peptide. See Sourcing and Verification.
Monitoring
- Symptom journal. Stool form (Bristol scale), pain frequency / intensity, post-meal symptoms, energy. The cleanest signal for whether the protocol is doing anything.
- hsCRP, fecal calprotectin (if IBD-adjacent). Inflammation markers track better than systemic bloodwork for gut-targeted protocols.
- CBC, CMP at baseline and end of cycle. Standard regardless of route.
- Bloodwork timing in the Bloodwork Panel Cheat Sheet.
Cross-references
- Injury Recovery - the broader BPC-157 framework, including the systemic SC use case for tendon / joint indications.
- Immune Resilience - the LL-37 framing, autoimmune contraindications, and Herxheimer management apply directly here.
- Cancer Risk and Growth Factors - per-mechanism risk frame for angiogenic compounds (BPC).
- Cycling Strategies - the on/off rationale for both BPC and LL-37.